NCT00501683View on ClinicalTrials.gov

A Single Dose Of GSK189075 Taken By Mouth Containing Small Amounts Of Radioactivity Studied In Healthy Male Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

November 30, 2006

Conditions
Type 2 Diabetes MellitusDiabetes Mellitus, Type 2
Interventions
DRUG

Radiolabelled GSK189075

Trial Locations (1)

53704

GSK Investigational Site, Madison

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY